Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at JMP Securities

JMP Securities assumed coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a research note published on Wednesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $4.00 price objective on the stock.

A number of other brokerages also recently issued reports on CNTX. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Context Therapeutics in a report on Monday, September 23rd. D. Boral Capital assumed coverage on shares of Context Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $9.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $6.33.

Context Therapeutics Stock Performance

CNTX stock opened at $1.21 on Wednesday. The company’s 50 day moving average price is $1.52 and its 200 day moving average price is $1.94. The firm has a market capitalization of $90.75 million, a price-to-earnings ratio of -1.33 and a beta of 2.10. Context Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). Equities analysts forecast that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Trading of Context Therapeutics

A number of large investors have recently bought and sold shares of CNTX. State Street Corp raised its holdings in shares of Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after buying an additional 19,800 shares during the last quarter. Renaissance Technologies LLC increased its position in Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after acquiring an additional 25,300 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Context Therapeutics in the 3rd quarter valued at about $89,000. Ally Bridge Group NY LLC raised its stake in Context Therapeutics by 159.8% during the 2nd quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock valued at $3,782,000 after acquiring an additional 1,160,281 shares during the last quarter. Finally, Affinity Asset Advisors LLC lifted its position in Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after acquiring an additional 1,290,323 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.